New insider activity at Cytokinetics ( (CYTK) ) has taken place on February 5, 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Executive Vice President of Research & Development, Fady Ibraham Malik, has sold 2,000 shares of Cytokinetics stock, amounting to a total sale value of $96,120.
Recent Updates on CYTK stock
In recent developments for Cytokinetics, Stifel initiated coverage with a positive outlook, citing that despite the stock being “out-of-favor” due to a controversial Royalty Pharma deal, its valuation has largely reset. Stifel expects a catalyst-rich year ahead, particularly with aficamten, which they consider a strong contender in the market for obstructive hypertrophic cardiomyopathy. Additionally, Cytokinetics announced the Phase 2 trial of CK-4021586, targeting heart failure with preserved ejection fraction, is open for enrollment. These developments indicate a strategic focus on advancing their drug pipeline and mitigating risks associated with their high-value opportunities.
More about Cytokinetics
YTD Price Performance: -0.95%
Average Trading Volume: 1,257,029
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.72B